

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name Tissue Dynamics * **Website** <https://www.tissuedynamics.com/> *

CEO name Einat Zisman * **Cell phone number** 050-5172233 *

Select a CATEGORY: Biotech/Pharma or Medical Devices or Health IT/Digital *

Select up to two SESSIONS per abstract from the list below *

5. AI tapestry: optimizing the interaction of AI and Biopharma

12. Bio Convergence - Everything That Rises Must Converge.

○ **Executive Summary / Investment Rational**

Tissue Dynamics developed a human-centric platform using human microtissue assembloids, sensors, and AI to address the pitfall of insufficient understanding of disease progression in treatments, resulting in 90% of drugs failing in clinical settings. The company has secured 4.5M USD and established a cutting-edge robotic platform, and has partnerships with ATCC and Rhenium to develop innovative treatments.

○ **Core Technology**

Tissue Dynamics is a biotechnology company advancing an animal-free autonomous drug development platform using bionic human microtissues to dramatically reduce the cost of drug development. The company's DynamiX system uses 3D human tissues embedded with electro-optical sensors that provide critical insight into human-specific mechanisms. Tissue Dynamics advanced new therapeutics for cancer, viral infection, arrhythmia, and rare genetic diseases.

○ **Product Profile/Pipeline**

Tissue Dynamics is developing novel therapies for diseases that lack informative animal models. Our product pipeline includes:

TD01, a biological therapy for Fanconi Anemia. The projected market size for TD01 is estimated at \$20B due to applications in Alzheimer's and NASH.

TD06, a small molecule for the treatment of CPVT with a potential market of \$5B annually. Both treatments were validated in human disease models.

○ **Business Strategy**

Tissue Dynamics' main business focus is the development of novel, human-relevant therapies. We have established the capability of our platform to identify and develop novel targets and validated our findings by clinical supporting data. In addition, we collaborate with pharma companies on the platform and plan to extend such collaborations, to increase awareness, accreditation, and datasets of our platform.

○ **What's Next?**

Tissue Dynamics is located in a 470 sqm facility in Rehovot, with a growing R&D team and USD 4.5M raised to date. TD is raising its Series A, with the aim to use the proceeds to facilitate the development of TD01 and TD06, as well as extend the identification of novel targets with human-relevant disease models and AI-driven insights.

